ProMIS positive 6‑month interim safety and biomarker data in Alzheimer's Phase 1b

 

ProMIS Neurosciences reports positive 6‑month interim safety and biomarker data from Phase 1b PRECISE‑AD trial of Alzheimer’s drug PMN310

• Blinded six‑month interim analysis showed no cases of ARIA‑E in patients receiving PMN310
• Biomarker data indicate early signs of target engagement for PMN310 in the PRECISE‑AD Phase 1b study
• Topline 12‑month safety and biomarker results from PRECISE‑AD are expected in Q1 2027

https://finviz.com/stock?t=PMN&p=d